Table 1.
Characteristics of subjects
| Time (W) | n | n (%) | GMT (S/CO) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male | Age groups | Types of vaccines | ||||||||
| 18–45 | 46–60 | >60 | Vero cell | CHO cell | Adenovial-vector | IgM | IgG | |||
| 1 | 82 | 43 (52.439) | 20 (24.390) | 38 (46.341) | 24 (29.269) | 76 (92.683) | 6 (7.317) | 0 (0.000) | 1.205 (+3.981, −3.981) | 1.933 (+3.061, −3.061) |
| 2 | 207 | 79 (38.164) | 60 (28.986) | 101 (48.792) | 46 (21.222) | 196 (94.686) | 10 (4.831) | 1 (0.483) | 1.497 (+3.810, −3.810) | 4.048 (+2.059, −2.059) |
| 3 | 209 | 89 (42.584) | 62 (29.665) | 92 (44.019) | 55 (26.316) | 204 (97.608) | 3 (1.435) | 2 (0.957) | 0.906 (+4.505, −4.505) | 3.526 (+1.890, −1.890)# |
| 4 | 152 | 62 (40.789) | 39 (25.658) | 86 (56.579) | 27 (17.763) | 147 (96.711) | 3 (1.974) | 2 (1.315) | 0.567 (+4.306, −4.306)* | 3.192 (+1.906, −1.906)# |
| 5–6 | 232 | 97 (41.810) | 82 (35.345) | 111 (47.845) | 39 (16.810) | 229 (98.707) | 2 (0.862) | 1 (0.431) | 0.418 (+3.680, −3.680)* | 2.892 (+1.956, −1.956)# |
| 7–8 | 135 | 53 (39.259) | 43 (31.852) | 64 (47.407) | 28 (20.741) | 134 (99.259) | 0 (0.000) | 1 (0.741) | 0.470 (+3.860, −3.860)* | 2.477 (+1.807, −1.807)# |
| 9–10 | 38 | 16 (42.105) | 11 (28.947) | 23 (60.526) | 4 (10.270) | 38 (100.000) | 0 (0.000) | 0 (0.000) | 0.237 (+3.965, −3.965)* | 2.325 (+1.721, −1.721)# |
| 11–25 | 38 | 12 (31.579) | 25 (65.789) | 13 (34.211) | 0 (0.000) | 38 (100.000) | 0 (0.000) | 0 (0.000) | 0.114 (+2.707, −2.707)* | 1.885 (+1.506, −1.506)# |
*P < 0.05, vs. IgM in second week; #P < 0.05, vs. IgG in second week.